High efficacy localized treatment of skin conditions like never before
Using advanced immuno-dermatology therapies, avoiding side effects common from systemic exposure to highly potent new drugs
Who we are
Our Advantage
Our Mission
CAGE Bio Inc. is a clinical-stage startup exploiting its proprietary deep eutectic ionic liquid platform to develop innovative products for dermatology, inflammation, and immunology.
Our Mission
Our Advantage
Our Mission
We believe that systemic exposure to drugs, especially in dermatology, should be an exception. Our mission is to develop localized treatment options that match the efficacy of the best systemic drugs with the safety of local, topical administration
Our Advantage
Our Advantage
Our Advantage
CAGE Bio’s proprietary deep eutectic ionic liquids (ILs) enable penetration of small and large molecules such as proteins and nucleic acids across the stratum corneum and deep into the skin. These ILs have excellent interaction with skin lipids and operate at a molecular scale which makes them superior to all other technologies for skin permeation.
OUR LEADERSHIP
Nitin Joshi, CEO
20+ years in drug development through approvals in the US and EU. Held senior positions at Elan, Alkermes, ALZA (J&J). Co-Founder, Incline Therapeutics acquired by The Medicines Company
Carmine J. Durham
Chief Strategy Officer
30+ years experience in pharma and med tech operations. Held senior positions at Knoll/BASF Pharma, Abbott Laboratories, and BoneCare Int’l. (acquired by Genzyme).
Co-Founder and former CEO of Zurex Pharma
Srini Sripada
Chief Commercial Officer
25+ years experience building iconic brands including Campbell Soup, Advil analgesics, & Vaseline skin care at blue-chip marketing organizations (P&G, Campbell Soup, Unilever & Pfizer) post MBA from Columbia Business School, New York
Welcome! Check out our latest news.
CAGE Bio Announces Phase 2b Trial for CGB-500 (1% Tofacitinib), a Breakthrough Topical JAK Inhibitor for Moderate to Severe Atopic Dermatitis